Platform-Powered Oncology Drug Development

Platform-Powered Oncology Drug Development

Platform-Powered Oncology Drug Development

Transforming the Future of Cancer Treatment

Explore Our Science

Explore Our Science

Explore Our Science

Explore Our Science

Transforming Cancer Treatment Through Pioneering Science

Transforming Cancer Treatment Through Pioneering Science

Transforming Cancer Treatment Through Pioneering Science

(About Us)

7 Primus Biosciences is an innovative oncology biotech distinguished by proprietary platforms and deep translational expertise. Our accomplished team transforms cutting-edge discoveries into advanced cancer therapies combining world-class scientific insight with breakthrough technology to deliver real hope for patients globally.


By partnering with leading academic and industry collaborators, we accelerate a robust pipeline designed to redefine cancer care and unlock exceptional value for stakeholders.

Proprietary Platforms
Proprietary Platforms
Targeted Oncology Expertise
Targeted Oncology Expertise
two people shaking hands
Global Collaboration
two people shaking hands
Global Collaboration

Innovations in Targeted Oncology

Inducing Cancer Cell Death Through BAK Activation
CombYSelect Platform for Efficient IgG Heterodimerization
Bispecific Antibody and Bispecific Antibody-Drug Conjugates

We are developing 7PB-100, a novel small molecule BAK activator designed to selectively induce apoptosis in tumors with high BAK expression. Preclinical studies demonstrate marked tumor suppression with minimal impact on normal tissues, highlighting its potential as both a standalone treatment and a synergistic agent in combination therapies.

purple and white abstract painting

The CombYSelect platform accelerates the creation of highly stable IgG heterodimers for next-generation bispecific antibodies and bispecific antibody-drug conjugates (BADCs). This proprietary, in silico, structure-guided approach produces long-lasting, functionally enhanced molecules capable of dual-targeting key cancer antigens, facilitating therapy customization and rapid pipeline expansion.

water droplets on glass during daytime

Through our proprietary CombYSelect platform, we create IgG-like bispecific antibodies that precisely target multiple tumor antigens for greater selectivity and sustained efficacy. Our bispecific ADCs (BADCs) combine these antibodies with various payloads, including 7PB-100, to enhance cancer targeting, minimize antigen escape, and reduce toxicity compared to conventional ADCs.

Innovations in Targeted Oncology

Inducing Cancer Cell Death Through BAK Activation
CombYSelect Platform for Efficient IgG Heterodimerization
Bispecific Antibody and Bispecific Antibody-Drug Conjugates

We are developing 7PB-100, a novel small molecule BAK activator designed to selectively induce apoptosis in tumors with high BAK expression. Preclinical studies demonstrate marked tumor suppression with minimal impact on normal tissues, highlighting its potential as both a standalone treatment and a synergistic agent in combination therapies.

purple and white abstract painting

The CombYSelect platform accelerates the creation of highly stable IgG heterodimers for next-generation bispecific antibodies and bispecific antibody-drug conjugates (BADCs). This proprietary, in silico, structure-guided approach produces long-lasting, functionally enhanced molecules capable of dual-targeting key cancer antigens, facilitating therapy customization and rapid pipeline expansion.

water droplets on glass during daytime

Through our proprietary CombYSelect platform, we create IgG-like bispecific antibodies that precisely target multiple tumor antigens for greater selectivity and sustained efficacy. Our bispecific ADCs (BADCs) combine these antibodies with various payloads, including 7PB-100, to enhance cancer targeting, minimize antigen escape, and reduce toxicity compared to conventional ADCs.

Leading the Future of Cancer Medicine

Leading the Future of Cancer Medicine

Our robust pipeline spans first-in-class small molecules, advanced bispecifics, and BADCs, each program designed to address high unmet needs and unlock new standards in oncology.

7PB-100

A first-in-class small molecule BAK activator designed for potent anti-tumor efficacy and minimal impact on normal cells.

7PB-200

IgG1-format bispecific antibody targeting undisclosed tumor-associated antigens (TAAs).

7PB-300

Bispecific antibody-drug conjugate combining dual targeting with precise payload delivery.

7PB-100

A first-in-class small molecule BAK activator designed for potent anti-tumor efficacy and minimal impact on normal cells.

7PB-200

IgG1-format bispecific antibody targeting undisclosed tumor-associated antigens (TAAs).

7PB-300

Bispecific antibody-drug conjugate combining dual targeting with precise payload delivery.

Our Strengths

Diverse R&D Programs

CombySelect Platform

Rigorous R&D Evaluation

Biomarker-Driven Patient Selection

Strategic Collaboration Network

Patient-Centered Philosophy

Explore Our Science

Explore Our Science

Explore Our Science

Explore Our Science

water droplets on a surface

Your Gateway to Precision Cancer Innovation

Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.

Interested in unlocking new possibilities? Connect with our team.

Let’s Talk With Us

water droplets on a surface

Your Gateway to Precision Cancer Innovation

Have questions or want to know more about our ground breaking targeted cancer therapeutics? Feel free to reach out to our dedicated team.

Interested in unlocking new possibilities? Connect with our team.

Let’s Talk With Us

water droplets on a surface

Your Gateway to Precision Cancer Innovation

Let’s Talk With Us

Interested in unlocking new possibilities? Connect with our team.